While many companies focus on enhancing existing drug development workflows ... generation projects for international clients ...

The FDA said it was “unable to approve the supplemental new drug application (sNDA) in its current form”, which tallies with ...

Researchers are testing a product commonly used to treat ticks and fleas on pets to target fly and mosquito larvae with the goal of helping reduce the spread of diseases carried by these insects.

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...

This study introduces a novel lignin-based hydrogel with controlled release and enhanced mechanical strength, leveraging ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Harmony Biosciences surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting ...